Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.024 | 0.7 |
mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.7 |
mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.7 |
mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.7 |
mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |